BioSpace News Archive

Business

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates

Alnylam Pharmaceuticals, Inc. announced its preliminary* fourth quarter and full year 2023 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.

January 7, 2024
·
9 min read
Business

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2023.

January 7, 2024
·
8 min read
Genetown

Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc.

January 7, 2024
·
3 min read
Genetown

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

Akoya Biosciences, Inc., The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets*.

January 7, 2024
·
5 min read
Biotech Bay

IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance

IDEAYA Biosciences, Inc. announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates.

January 7, 2024
·
4 min read
Business

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance

RxSight, Inc. announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.

January 7, 2024
·
5 min read
Calliditas to present at 42nd Annual JP Morgan Healthcare Conference

Calliditas Therapeutics AB announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.

January 7, 2024
·
1 min read
Business

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2023 revenue results, cash and investments at year end 2023, and provided 2024 guidance on select key financial metrics including net cash used in operations.

January 7, 2024
·
9 min read
QIAGEN announces plans to return approximately $300 million to shareholders

QIAGEN N.V. announced a plan to return up to approximately $300 million to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split.

January 7, 2024
·
5 min read
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd has added three new endocrinology therapies to its specialist portfolio, following an exclusive distribution agreement with Danish company Ascendis Pharma A/S.

January 7, 2024
·
10 min read